Table 1 Detailed information of the combination therapy of ICI and inhibitors of key molecules.
From: Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
Drug | NCT No. | Tumor | Phase | Status | Therapy | Conclusion |
|---|---|---|---|---|---|---|
Anti- CXCR2 | ||||||
 Reparixin | NCT02001974 | HER 2 Negative Metastatic Breast Cancer | I | Completed | Paclitaxel+Reparixin | / |
 Reparixin | NCT01861054 | Early Breast Cancer | II | Terminated | Reparixin | / |
 SX-682 | NCT03161431 | Metastatic Melanoma | I | Recruiting | SX-682 + Pembrolizumab | / |
 SX-682 | NCT04477343 | Metastatic Pancreatic Ductal Adenocarcinoma | I | Recruiting | SX-682 + Nivolumab | / |
 SX-682 | NCT04574583 | Advanced Solid Tumors | I/II | Recruiting | SX-682 + M7824 + CV301 | / |
 SX-682 | NCT04599140 | RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer | I/II | Recruiting | SX-682 + Nivolumab | / |
 AZD5069 | NCT02583477 | Metastatic Pancreatic Ductal Carcinoma | I/II | Completed | MEDI4736 + AZD5069 | 1/18 ORR (durvalumab + CXCR1/2 inhibitor) |
 AZD5069 | NCT02499328 | Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck | II | Active, not recruiting | MEDI4736 + AZD5069 | / |
Anti-CXCR4 | ||||||
 Plerixafor | NCT04177810 | Metastatic Pancreatic Cancer | II | Recruiting | Cemiplimab + Plerixafor | / |
 Plerixafor | NCT04058145 | Refractory Head and Neck Squamous Cell Carcinoma | II | Withdrawn | Pembrolizumab+AMD3100 | / |
 Plerixafor | NCT03240861 | Advanced Cancer | I | Recruiting | Aldesleuki + Busulfan + LV-NYESO TCR + sr39TK PBSC IV and RV-NYESO TCR PBMC IV + Filgrastim + Fludarabine + Plerixafor | / |
 Motixafortide (BL-8040) | NCT02826486 | Metastatic Pancreatic Adenocarcinoma | II | Active, not recruiting | BL-8040 + Pembrolizumab; BL-8040 + Pembrolizumab + Onivyde | / |
 Motixafortide (BL-8040) | NCT03154827 | Acute Myeloid Leukemia Who Are 60 Years or Older | I/II | Terminated | BL-8040 + Atezolizumab | / |
 Motixafortide (BL-8040) | NCT02907099 | Metastatic Pancreatic Cancer | II | Active, not recruiting | BL-8040 + Pembrolizumab | / |
 Motixafortide (BL-8040) | NCT03193190 | Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) | I/II | Recruiting | Atezolizumab + BL-8040 | / |
 LY2510924 | NCT02737072 | Solid Tumors | I | Terminated | 20 mg LY2510924 + 1500 mg Durvalumab; 30 mg LY2510924 + 1500 mg Durvalumab; 40 mg LY2510924 + 1500 mg Durvalumab | 0/3;0/3;0/3 ORRs in each arms. 3/3; 1/3; 0/3 DCRs in each arms |
 BMS-936564 | NCT02472977 | Solid Tumors | I/II | Terminated | BMS-936564 (Ulocuplumab) + Nivolumab (SCLC); BMS-936564 (Ulocuplumab) + Nivolumab (PAC) | 0/6 and 0/27 ORRs in PAC. |
Anti-TGF-β | ||||||
 ABBV-151 | NCT03821935 | Locally Advanced or Metastatic Solid Tumors | I | Recruiting | ABBV-151 + Budigalimab | / |
 Pirfenidone | NCT04467723 | Stage IV and recurrent NSCLC | I/II | Not yet recruiting | Atezolizumab + Pirfenidone | / |
Anti-TGF-β (mAb) | ||||||
 NIS793 | NCT02947165 | Advanced Malignancies | I | Active, not recruiting | NIS793 + PDR001 | / |
 NIS793 | NCT04390763 | First-line Metastatic Pancreatic Ductal Adenocarcinoma | II | Recruiting | NIS793 + spartalizumab + gemcitabine + nab-paclitaxel; | / |
 SAR439459 | NCT03192345 | Advanced Solid Tumors | I | Recruiting | SAR439459 + cemiplimab | / |
 SAR439459 | NCT04729725 | Advanced or Unresectable Solid Tumors | I | Recruiting | SAR439459 + cemiplimab | / |
Anti-TGF-β and PD-L1 | ||||||
 Bintrafusp alfa (M7824) | NCT04633252 | Metastatic Castration Sensitive and Castration Resistant Prostate Cancer | I/II | Recruiting | Docetaxel + M9241; Docetaxel + M9241 + M7824 | / |
 Bintrafusp alfa (M7824) | NCT03631706 | Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) | III | Active, not recruiting | M7824 + Pembrolizumab | / |
 Bintrafusp alfa (M7824) | NCT03840902 | Unresectable Stage III NSCLC | II | Recruiting | cCRT + M7824 followed by M7824; | / |
 Bintrafusp alfa (M7824) | NCT03833661 | Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) | II | Active, not recruiting | M7824 | / |
 Bintrafusp alfa (M7824) | NCT04574583 | Advanced Solid Tumors | I/II | Recruiting | SX-682 + M7824 + CV301 | / |
 Bintrafusp alfa (M7824) | NCT03524170 | Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer | I | Recruiting | M7824 + radiation therapy | / |
 Bintrafusp alfa (M7824) | NCT03554473 | Relapsed Small Cell Lung Cancers | I/II | Recruiting | M7824; M7824 + Topotecan; M7824 + Temozolomide | / |
 Bintrafusp alfa (M7824) | NCT04296942 | Advanced Stage Breast Cancer (BrEAsT) | I | Recruiting | M7824 + BN-Brachyury; M7824 + BN-Brachyury + T-DM1; M7824 + BN-Brachyury + T-DM1 + Entinostat | / |
 Bintrafusp alfa (M7824) | NCT04327986 | Advanced Pancreas Cancer | I/II | Not yet recruiting | M9241 + M7824; M9241 + M7824+ SBRT | / |
 Bintrafusp alfa (M7824) | NCT04432597 | HPV Associated Cancers | I/II | Recruiting | HPV vaccine + M7824 | / |
 Bintrafusp alfa (M7824) | NCT03579472 | Metastatic Triple Negative Breast Cancer | I | Recruiting | Bintrafusp alfa + eribulin mesylate | / |
 Bintrafusp alfa (M7824) | NCT04066491 | 1L Biliary Tract Cancer (BTC) | II/III | Recruiting | Bintrafusp alfa + Gemcitabine + Cisplatin; Bintrafusp alfa + Gemcitabine + Cisplatin | / |
 Bintrafusp alfa (M7824) | NCT04235777 | Adults With Metastatic Non-Prostate Genitourinary Malignancies | I | Recruiting | M7824 + M9241 if appropriate; M7824 + M9241 (if appropriate) + sequential SBRT; M7824 + M9241 (if appropriate) + concurrent SBRT | / |
 Bintrafusp alfa (M7824) | NCT02517398 | Metastatic or Locally Advanced Solid Tumors | I | Active, not recruiting | M7824 | / |
 Bintrafusp alfa (M7824) | NCT03620201 | Stage II-III HER2 Positive Breast Cancer | I | Recruiting | M7824 | / |
 Bintrafusp alfa (M7824) | NCT02699515 | Metastatic or Locally Advanced Solid Tumors | I | Active, not recruiting | M7824 | / |
 Bintrafusp alfa (M7824) | NCT04489940 | High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | II | Recruiting | M7824 | / |
 Bintrafusp alfa (M7824) | NCT03436563 | Advanced Solid Tumors With Microsatellite Instability | I/II | Recruiting | M7824 | / |
 Bintrafusp alfa (M7824) | NCT04246489 | Platinum-Experienced Cervical Cancer | II | Active, not recruiting | M7824 | / |
 Bintrafusp alfa (M7824) | NCT04708470 | Advanced Cancer | I/II | Not yet recruiting | Entinostat, + NHS-IL12 + Bintrafusp alfa | / |
 Bintrafusp alfa (M7824) | NCT04491955 | Advanced Small Bowel and Colorectal Cancers | II | Recruiting | CEA/ MUC1 Vaccines + M7824 + N-803; CEA/ MUC1 Vaccines + M7824 + N-803 + NHSIL12; | / |
 Bintrafusp alfa (M7824) | NCT03427411 | HPV Associated Malignancies | II | Active, not recruiting | M7824 | / |
 Bintrafusp alfa (M7824) | NCT04287868 | Advanced HPV Associated Malignancies | I/II | Recruiting | PDS0101 + NHS IL12 + M7824 | / |
 Bintrafusp alfa (M7824) | NCT03840915 | Stage IV NSCLC | I/II | Active, not recruiting | Cisplatin or Carboplatin + Pemetrexed + M7824; Carboplatin + Paclitaxel or Nab-paclitaxel + M7824; Cisplatin or Carboplatin + Gemcitabine + M7824; Docetaxel + M7824 | / |
 Bintrafusp alfa (M7824) | NCT04417660 | Thymoma and Thymic Carcinoma | II | Recruiting | M7824 | / |
 Bintrafusp alfa (M7824) | NCT04247282 | Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection | I/II | Recruiting | M7824; M7824 + TriAd vaccine; M7824 + TriAd vaccine + N-803 | / |
 Bintrafusp alfa (M7824) | NCT04501094 | Urothelial Carcinoma | II | Recruiting | M7824 | / |
 Bintrafusp alfa (M7824) | NCT04560686 | Untreated Resectable Non-small Cell Lung Cancer | II | Recruiting | Bintrafusp alfa + surgical resection | / |
 Bintrafusp alfa (M7824) | NCT03493945 | Advanced Prostate cancer | I/II | Recruiting | M7824 + ALT-803; M7824 + BN-Brachyury; M7824 + BN-Brachyury + ALT-803; M7824 + BN-Brachyury + ALT-803 + Epacadostat | / |
 Bintrafusp alfa (M7824) | NCT04349280 | Metastatic or Locally Advanced Urothelial Cancer | I | Recruiting | Bintrafusp alfa | / |
 Bintrafusp alfa (M7824) | NCT03315871 | Recurrent Prostate Cancer | II | Recruiting | PROSTVAC-V + PROSTVAC-F + M7824 + CV301; | / |
 Bintrafusp alfa (M7824) | NCT04727541 | Resectable Biliary Tract Cancer | II | Not yet recruiting | Neoadjuvant therapy with Bintrafusp alfa | / |
 Bintrafusp alfa (M7824) | NCT04551950 | Cervical Cancer | I | Recruiting | M7824+cisplatin; M7824 + cisplatin or carboplatin + paclitaxel; M7824+cisplatin+ radiotherapy | / |
 Bintrafusp alfa (M7824) | NCT03451773 | Advanced Adenocarcinoma of the Pancreas | I/II | Completed | Gemcitabine + M7824 | / |
 Bintrafusp alfa (M7824) | NCT04595149 | Esophageal Squamous Cell Carcinoma | II | Recruiting | Bintrafusp alfa + Paclitaxel + Carboplatin | / |
 Bintrafusp alfa (M7824) | NCT04220775 | Recurrent or Second Primary Head and Neck Squamous Cell Cancer | I/II | Recruiting | Bintrafusp alfa + SBRT | / |
 Bintrafusp alfa (M7824) | NCT04756505 | Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer | I | Not yet recruiting | Bintrafusp alfa + NHS-IL12 + radiation therapy | / |
 Bintrafusp alfa (M7824) | NCT04396535 | Advanced Non-small Cell Lung Cancer | II | Recruiting | Docetaxel + B zintrafusp alfa | / |
 Bintrafusp alfa (M7824) | NCT04789668 | Mutilple Stage IV cancers | I/II | Recruiting | bintrafusp alfa + Pimasertib | / |
 Bintrafusp alfa (M7824) | NCT04648826 | Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies | I/II | Not yet recruiting | Azacytidine+ Bintrafusp alfa | / |
 Bintrafusp alfa (M7824) | NCT03707587 | Recurrent Respiratory Papillomatosis | II | Active, not recruiting | M7824 | CR: 0/7 and 0/2 in ICI naïve patients and ICI refractory; PR: 1/7 and 0/2 |
 Bintrafusp alfa (M7824) | NCT04303117 | Advanced Kaposi Sarcoma | I/II | Recruiting | NHSIL12 + M7824 | / |
 Bintrafusp alfa (M7824) | NCT04428047 | Operable and Untreated Head and Neck Squamous Cell Carcinoma | II | Recruiting | M7824 | / |
 Bintrafusp alfa (M7824) | NCT04708067 | Advanced Intrahepatic Cholangiocarcinoma | I | Not yet recruiting | Hypofractionated radiation + Bintrafusp alfa | / |
Anti-TGFβR1 | ||||||
 Galunisertib | NCT02734160 | Metastatic Pancreatic Cancer | I | Completed | Galunisertib + Durvalumab | / |
 Galunisertib | NCT02423343 | Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | I/II | Completed | Galunisertib + Nivolumab | / |
 Vactosertib (TEW-7197) | NCT03724851 | Metastatic Colorectal or Gastric Cancer | I/II | Recruiting | TEW-7197 + Pembrolizumab | / |
 Vactosertib (TEW-7197) | NCT03732274 | Advanced NSCLC | I/II | Active, not recruiting | TEW-7197 + Durvalumab | / |
 Vactosertib (TEW-7197) | NCT04064190 | Urothelial Carcinoma | II | Not yet recruiting | Vactosertib + Durvalumab | / |
 Vactosertib (TEW-7197) | NCT04515979 | PD-L1 Positive NSCLC | II | Recruiting | Vactosertib + Pembrolizumab | / |
 LY3200882 | NCT04158700 | Advanced Cancer | I/II | Withdrawn | LY3200882 + Pembrolizumab | / |
Anti-IL-6R | ||||||
 Tocilizumab | NCT04691817 | Non-Small Cell Lung Cancer | I/II | Not yet recruiting | Atezolizumab + Tocilizumab | / |
 Tocilizumab | NCT04258150 | Advanced Pancreatic Cancer | II | Active, not recruiting | Nivolumab + Ipilimumab + Tocilizumab + Radiation | / |
 Tocilizumab | NCT04524871 | Advanced Liver Cancers | I/II | Recruiting | Atezolizumab + Bevacizumab + Tocilizumab | / |
 Tocilizumab | NCT03588936 | Relapsed Hematological Malignancy | I | Terminated | Nivolumab + Tocilizumab | / |
 Tocilizumab | NCT03821246 | Prostate Cancer | II | Recruiting | Atezolizumab + Tocilizumab | / |
 Tocilizumab | NCT03708224 | Squamous Cell Carcinoma of the Head and Neck | II | Recruiting | Atezolizumab + Tocilizumab | / |
 Tocilizumab | NCT03424005 | Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer | I/II | Recruiting | Atezolizumab + Nab-Paclitaxel + Tocilizumab | / |
 Tocilizumab | NCT04729959 | Recurrent Glioblastoma | II | Not yet recruiting | Atezolizumab + Tocilizumab + Radiation; Atezolizumab + Tocilizumab + Radiation + Surgery | / |
 Tocilizumab | NCT03866239 | Metastatic Colorectal Adenocarcinoma | I | Recruiting | Obinutuzumab + Cibisatamab + Atezolizumab + Tocilizumab | / |
 Tocilizumab | NCT03869190 | Urothelial Carcinoma | I/II | Recruiting | Atezolizumab + Tocilizumab | / |
 Tocilizumab | NCT03337698 | Metastatic Non-Small Cell Lung Cancer | I/II | Recruiting | Atezolizumab + RO6958688 + Tocilizumab | / |
 Tocilizumab | NCT03999749 | Unresectable Stage III or Stage IV Melanoma | II | Recruiting | Ipilimumab + Nivolumab + Tocilizumab | / |
 Tocilizumab | NCT03533283 | Non-Hodgkins Lymphoma | I | Recruiting | Glofitamab + Atezolizumab + Obinutuzumab + Tocilizumab | / |
Anti-Arginase | ||||||
 INCB001158 | NCT03910530 | Advanced Solid Tumors | I | Active, not recruiting | Retifanlimab + INCB001158 | / |
 INCB001158 | NCT03361228 | Advanced Solid Tumors | I/II | Terminated | INCB001158 + Epacadostat + Pembrolizumab | / |
 INCB001158 | NCT02903914 | Advanced/Metastatic Solid Tumors | I/II | Active, not recruiting | INCB001158 + Pembrolizumab | / |
Anti-CD39 | ||||||
 IPH5201 | NCT04261075 | Advanced Solid Tumors | I | Recruiting | IPH5201 + Durvalumab; IPH5201 + Durvalumab + Oleclumab | / |
 TTX-030 | NCT04306900 | Advanced Cancers | I | Recruiting | TTX-030 + Budigalimab; TTX-030 + Budigalimab + Docetaxel; TTX-030 + Budigalimab + mFOLFOX6 | / |
 TTX-030 | NCT03884556 | Advanced Cancers | I | Recruiting | TTX-030 + Pembrolizumab | / |
Anti-CD39 (mAb) | ||||||
 SRF617 | NCT04336098 | Advanced Solid Tumors | I | Recruiting | SRF617 + Pembrolizumab | / |
Anti-CD73 (mAb) | ||||||
 CPI-006 | NCT03454451 | Advanced Cancers | I | Recruiting | CPI-006 + Pembrolizumab | / |
 AB680 | NCT04104672 | Gastrointestinal Malignancies | I | Recruiting | AB680 + Zimberelimab + Nab-paclitaxel + Gemcitabine | / |
 AB680 | NCT04381832 | Metastatic Castrate Resistant Prostate Cancer | I/II | Recruiting | Etrumadenant + Zimberelimab | / |
 AB680 | NCT04660812 | Metastatic Colorectal Cancer | I/II | Recruiting | Etrumadent+ Zimberelimab + AB680 | / |
 TJ004309 | NCT04322006 | Advanced Solid Tumor | I/II | Recruiting | PD-1 monoclonal antibody + TJ004309 | / |
 TJ004309 | NCT03835949 | Advanced or Metastatic Cancer | I | Recruiting | TJ004309 + Atezolizumab | / |
 BMS-986179 | NCT02754141 | Solid Tumor | I/II | Active, not recruiting | BMS-986179 + Nivolumab | / |
 Oleclumab (MEDI9447) | NCT02503774 | Select Advanced Solid Tumors | I | Completed | Oleclumab + Durvalumab | / |
 Oleclumab (MEDI9447) | NCT03611556 | Metastatic Pancreatic Adenocarcinoma | I/II | Recruiting | Oleclumab + Durvalumab + mFOLFOX | / |
 Oleclumab (MEDI9447) | NCT03773666 | Muscle-invasive Bladder Cancer | I | Recruiting | Durvalumab + Oleclumab | / |
 Oleclumab (MEDI9447) | NCT04262375 | Non Small Cell Lung Cancer; Renal Cell Carcinoma | II | Withdrawn | Durvalumab + Oleclumab | / |
 Oleclumab (MEDI9447) | NCT04262388 | Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck | II | Withdrawn | Durvalumab + Oleclumab | / |
 Oleclumab (MEDI9447) | NCT03616886 | Triple Negative Breast Cancer | I/II | Recruiting | Paclitaxel + Carboplatin + Durvalumab + Oleclumab | / |
 Oleclumab (MEDI9447) | NCT03267589 | Relapsed Ovarian Cancer | II | Recruiting | Durvalumab + Oleclumab | / |
 Oleclumab (MEDI9447) | NCT04089553 | Prostate Cancer | II | Recruiting | AZD4635 + Durvalumab + Oleclumab | / |
 Oleclumab (MEDI9447) | NCT04668300 | Recurrent, Refractory, or Metastatic Sarcoma | II | Recruiting | Durvalumab + Oleclumab | / |
 Oleclumab (MEDI9447) | NCT03875573 | Luminal B Breast Cancer | II | Active, not recruiting | Chemotherapy & pre-op radiotherapy + Durvalumab + Oleclumab | / |
 Oleclumab (MEDI9447) | NCT03833440 | Non-small Cell Lung Cancer | II | Recruiting | Durvalumab + MEDI9447 | / |
 Oleclumab (MEDI9447) | NCT03819465 | Untreated NSCLC | I | Active, not recruiting | Durvalumab + Oleclumab; Durvalumab + investigator's choice of chemotherapy + Oleclumab | / |
 Oleclumab (MEDI9447) | NCT04068610 | Metastatic Microsatellite-stable Colorectal Cancer | I/II | Active, not recruiting | FOLFOX + Bevacuzimab + Durvalumab + Oleclumab | / |
 Oleclumab (MEDI9447) | NCT03822351 | NSCLC | II | Active, not recruiting | Durvalumab + Oleclumab | / |
 Oleclumab (MEDI9447) | NCT03742102 | Metastatic Triple Negative Breast Cancer | I/II | Recruiting | Durvalumab + Paclitaxel + Oleclumab | / |
 Oleclumab (MEDI9447) | NCT02740985 | Advanced Solid Malignancies | I | Active, not recruiting | AZD4635 + Durvalumab + Oleclumab | / |
 Oleclumab (MEDI9447) | NCT04145193 | Microsatellite-stable Colorectal Cancer | II | Withdrawn | mFOLFOX6 + Durvalumab + Oleclumab + Monalizumab | / |
 Oleclumab (MEDI9447) | NCT03334617 | NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy | II | Recruiting | Durvalumab + Oleclumab | / |
 NZV930 (SRF373) | NCT03549000 | Advanced Malignancies | I | Recruiting | NZV930 + PDR001; NZV930 + NIR178 + PDR001 | / |
 LY-3475070 | NCT04148937 | Advanced Cancer | I | Recruiting | LY3475070 + Pembrolizumab | / |
Anti-COX-2 | ||||||
 Celecoxib | NCT03728179 | Advanced TIL-negative Solid Tumors | I | Recruiting | RT + Cyclophosphamide + Nivolumab + Celecoxib/;RT + Nivolumab + Ipilimumab or Cyclophosphamide + Celecoxib; RT + Ipilimumab + Nivolumab + Celecoxib | / |
 Celecoxib | NCT04348747 | Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | II | Not yet recruiting | Anti-HER2/3 dendritic cell vaccine + Celecoxib + Pembrolizumab + recombinant interferon alfa-2b + Rintatolimod | / |
 Celecoxib | NCT03599453 | Metastatic Triple-Negative Breast Cancer | Early I | Active, not recruiting | Celecoxib + Recombinant Interferon Alfa-2b + Rintatolimod + Pembrolizumab | / |
 Celecoxib | NCT03026140 | Early Stage Colon Cancer | II | Recruiting | Nivolumab + Ipilimumab + Celecoxib | / |
 Celecoxib | NCT03638297 | MSI-H/dMMR or High TMB Colorectal Cancer | II | Recruiting | PD-1 antibody + Cox inhibitor | / |